Drug Trial Radar · NCT07184385
A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition
Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 31, 2026
Primary completion
Jun 30, 2027
Study completion Sep 30, 2027
Sponsor
- Lead sponsor
- StemCyte, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
REGENECYTE (HPC, Cord Blood) for treatment in patients with post-COVID.
Conditions
- Long COVID
- Post-COVID-19 Condition
- Post-COVID Syndrome
- Post-COVID Condition
Interventions
REGENECYTEBiological
HPC, Cord Blood
PlaceboBiological
Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of efficacyTime frame: Week
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.